COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study
By
Zahra Ghavami
Mahboubeh Haddad
Fereshte Sheybani
Matin Shirazinia
Maliheh Dadgar Moghadam
November 3, 2025
Clinical Scorecard: Mucormycosis Linked to COVID-19: Analyzing Mortality Risk Factors in a Retrospective Cohort Analysis
At a Glance
Category Detail
Condition COVID-19-associated mucormycosis (CAM), a severe fungal infection complicating COVID-19 Key Mechanisms Immune suppression from COVID-19 and corticosteroid use increases susceptibility to invasive mucormycosis; diabetes mellitus is a major comorbidity Target Population Adult patients with confirmed COVID-19 and histopathologically confirmed mucormycosis Care Setting Tertiary referral hospital setting managing COVID-19 and invasive fungal infections
Key Highlights
High mortality observed in CAM with one-month survival at 61.7%, declining to ~50% at six and twelve months Elevated C-reactive protein (CRP) levels predict increased mortality risk in CAM patients Prolonged antifungal treatment, especially with posaconazole, is associated with reduced mortality Guideline-Based Recommendations
Diagnosis
Confirm COVID-19 diagnosis by RT-PCR Diagnose mucormycosis via histopathological evidence of broad, non-septate hyphae with right-angle branching Use imaging and clinical findings to support diagnosis Management
Prompt initiation of antifungal therapy, including posaconazole Prolonged duration of antifungal treatment to improve survival Careful use of corticosteroids balancing COVID-19 benefits and fungal infection risks Monitoring & Follow-up
Monitor CRP levels as a prognostic marker for mortality risk Regular clinical assessment for signs of palatal necrosis and disease progression Follow-up survival status at multiple time points up to one year Risks
Diabetes mellitus significantly increases susceptibility to CAM Use of corticosteroids increases risk of mucormycosis development Presence of palatal necrosis is associated with higher mortality risk Patient & Prescribing Data
Adults hospitalized with COVID-19-associated mucormycosis, predominantly with diabetes mellitus
Use of posaconazole significantly reduces mortality risk (HR: 0.16); longer antifungal treatment duration correlates with improved survival
Clinical Best Practices
Early diagnosis of mucormycosis in COVID-19 patients, especially those with diabetes and corticosteroid exposure Risk stratification using CRP levels and clinical signs such as palatal necrosis Implement prolonged antifungal therapy tailored to patient response Multidisciplinary management involving infectious disease specialists and endocrinologists References
